Method for testing a therapeutic or preventive agent for hyperlipidemia

• US 20030017488A1
• Filed: 06/06/2002
• Published: 01/23/2003
• Est. Priority Date: 12/09/1999
• Status: Abandoned Application

• Current Assignee: Sankyo Company Limited (Daiichi Sankyo Company Limited)
• Original Assignee: Sankyo Company Limited (Daiichi Sankyo Company Limited)
• Inventors: Ando, Yosuke, Koishi, Ryuta, Furukawa, Hidehiko, Ono, Mitsuru, Horikoshi, Hiroyoshi, Fujiwara, Toshihiko
• Application Number:
  US10/164,030
• Publication Number:
  US 20030017488A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: A01K 2267/0362 Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 16/22 against growth factors ; against growth regulators
• CPC Class Codes: C12N 2799/022 where the vector is derived from an adenovirus
• CPC Class Codes: G01N 2500/20 cell-free systems
• CPC Class Codes: G01N 2800/044 Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
• CPC Class Codes: G01N 33/50 Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q
• CPC Class Codes: G01N 33/5008 for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
• CPC Class Codes: G01N 33/502 for testing non-proliferative effects
• CPC Class Codes: G01N 33/5023 on expression patterns
• CPC Class Codes: G01N 33/5067 Liver cells
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere

Abstract

A method for testing a therapeutic or preventive agent for hyperlipidemia, and a nucleic acid probe, a primer, and an antibody which are used in the method. Specifically, a method for testing the effect of a test substance as a therapeutic or preventive agent for hyperlipidemia by expression of a gene having a sequence as set forth in SEQ ID No. 1 or SEQ ID No. 2 of the Sequence Listing which participates in regulation of neutral-fat concentration in the blood of a mammal, and a nucleic acid probe, primer or antibody used for the method. The present invention makes it possible to search for a candidate substance for a therapeutic or preventive agent for hyperlipidemia.

Claims

1. A method for testing an effect of a substance as a therapeutic or preventive agent for hyperlipidemia comprising:

(i) culturing cells in the presence or absence of a test substance;

(ii) detecting the amount of expression of a mRNA which has a nucleotide sequence of one of the following sequences (a) to (e), wherein t in the sequence is read as u, in the cultured cells obtained in step (i);

(a) a nucleotide sequence having the nucleotide numbers 47-1411 of SEQ ID No. 1 of the Sequence Listing;

(b) a nucleotide sequence having the nucleotide numbers 78-1457 of SEQ ID No. 3 of the Sequence Listing;

(c) a nucleotide sequence of DNA incorporated into a phagemid carried by transformed Escherichia coli E.coli pBK/m55-1 SANK72199 (FERM BP-6940);

(d) a nucleotide sequence of DNA incorporated into a phagemid carried by transformed Escherichia coli E.coli pTrip/h55-1 SANK72299 (FERM BP-6941);

(e) a nucleotide sequence which hybridizes with the polynucleotide consisting essentially of an antisense sequence of the nucleotide sequence of one of the nucleotide sequences (a) to (d) under stringent conditions, and encodes a polypeptide having an activity of raising neutral fat concentration in blood; and

(iii) comparing the amount of expression of mRNA between the cells cultured in the absence of the substance and the cells cultured in the presence of the substance, as a result of detection step (ii).

2. The method according to claim 1, wherein the cultured cell originates from a liver.

3. The method according to claim 1, wherein the cultured cell originates from a primate or a rodent animal.

4. The method according to claim 2, wherein the cultured cell originates from a primate or a rodent animal.

5. The method according to claim 3, wherein the cultured cell originates from a human or a mouse.

6. The method according to claim 4, wherein the cultured cell originates from a human or a mouse.

7. The method according to claim 1, wherein the amount of mRNA expressed is detected by Northern blotting, dot blotting or slot blotting.

8. The method according to claim 2, wherein the amount of mRNA expressed is detected by Northern blotting, dot blotting or slot blotting.

9. The method according to claim 3, wherein the amount of mRNA expressed is detected by Northern blotting, dot blotting or slot blotting.

10. The method according to claim 4, wherein the amount of mRNA expressed is detected by Northern blotting, dot blotting or slot blotting.

11. The method according to claim 5, wherein the amount of mRNA expressed is detected by Northern blotting, dot blotting or slot blotting.

12. The method according to claim 6, wherein the amount of mRNA expressed is detected by Northern blotting, dot blotting or slot blotting.

13. The method according to claim 1, wherein the amount of mRNA expressed is detected by RT-PCR.

14. The method according to claim 2, wherein the amount of mRNA expressed is detected by RT-PCR.

15. The method according to claim 3, wherein the amount of mRNA expressed is detected by RT-PCR.

16. The method according to claim 4, wherein the amount of mRNA expressed is detected by RT-PCR.

17. The method according to claim 5, wherein the amount of mRNA expressed is detected by RT-PCR.

18. The method according to claim 6, wherein the amount of mRNA expressed is detected by RT-PCR.

19. The method according to claim 1, wherein the amount of mRNA expressed is detected by a ribonuclease protection assay.

20. The method according to claim 2, wherein the amount of mRNA expressed is detected by a ribonuclease protection assay.

21. The method according to claim 3, wherein the amount of mRNA expressed is detected by a ribonuclease protection assay.

22. The method according to claim 4, wherein the amount of mRNA expressed is detected by a ribonuclease protection assay.

23. The method according to claim 5, wherein the amount of mRNA expressed is detected by a ribonuclease protection assay.

24. The method according to claim 6, wherein the amount of mRNA expressed is detected by a ribonuclease protection assay.

25. The method according to claim 1, wherein the amount of mRNA expressed is detected by a run-on assay.

26. The method according to claim 2, wherein the amount of mRNA expressed is detected by a run-on assay.

27. The method according to claim 3, wherein the amount of mRNA expressed is detected by a run-on assay.

28. The method according to claim 4, wherein the amount of mRNA expressed is detected by a run-on assay.

29. The method according to claim 5, wherein the amount of mRNA expressed is detected by a run-on assay.

30. The method according to claim 6, wherein the amount of mRNA expressed is detected by a run-on assay.

31. A polynucleotide having a nucleotide sequence which hybridizes to a mRNA containing a nucleotide sequence selected from the following sequences (a) to (d), wherein t in the sequence is read as u, under stringent conditions, excluding nucleotide sequences in the following (a) to (d):

(a) a nucleotide sequence having the nucleotide numbers 47-1411 of SEQ ID No. 1 of the Sequence Listing;

(b) a nucleotide sequence having the nucleotide numbers 78-1457 of SEQ ID No. 3 of the Sequence Listing;

(c) a nucleotide sequence of DNA incorporated into a phagemid carried by transformed Escherichia coli E.coli pBK/m55-1 SANK72199 (FERM BP-6940);

(d) a nucleotide sequence of DNA incorporated into a phagemid carried by transformed Escherichia coli E.coli pTrip/h55-1 SANK72299 (FERM BP-6941).

32. A DNA consisting essentially of at least 15 nucleotides of the nucleotide sequence having the nucleotide numbers 47-1411 of SEQ ID No. 1 of the Sequence Listing wherein one or more of nucleotides are deleted at one end or both ends thereof.

33. A DNA consisting essentially of at least 15 nucleotides of the nucleotide sequence having the nucleotide numbers 78-1457 of SEQ ID No. 3 of the Sequence Listing wherein one or more of nucleotides are deleted at one end or both ends.

35. The method according to claim 34, wherein the antibody which specifically recognizes a polypeptide consisting essentially of the amino acid sequence encoded by any one of the sequences (a) to (e) or a part thereof is an antibody which specifically recognizes a polypeptide which consists essentially of the amino acid sequence having the amino acid numbers 17-455 of SEQ ID No. 2 of the Sequence Listing or a part thereof, a polypeptide which consists essentially of the amino acid sequence having the amino acid numbers 19-455 of SEQ ID No. 2 of the Sequence Listing or a part thereof, or a polypeptide which consists essentially of the amino acid sequence having the amino acid numbers 17-460 of SEQ ID No. 4 of the Sequence Listing or a part thereof.

36. The method according to claim 34, wherein the antibody which specifically recognizes a polypeptide consisting essentially of the amino acid sequence encoded by one of the sequences (a) to (e) or a part thereof is an antibody which specifically recognizes an amino acid sequence having amino acid numbers 1-13 of SEQ ID No. 9 of the Sequence Listing or the amino acid numbers 1-14 of SEQ ID No. 10 of the Sequence Listing.

37. The method according to claim 35, wherein the antibody which specifically recognizes a polypeptide consisting essentially of the amino acid sequence encoded by one of the sequences (a) to (e) or a part thereof is an antibody which specifically recognizes an amino acid sequence having amino acid numbers 1-13 of SEQ ID No. 9 of the Sequence Listing or the amino acid numbers 1-14 of SEQ ID No. 10 of the Sequence Listing.

38. The method according to claim 34, wherein a method for detecting using the antibody which specifically recognizes a polypeptide consisting essentially of an amino acid sequence encoded by one of the sequences (a) to (e) or a part thereof is Western blotting, a dot blotting or a slot blotting.

39. The method according to claim 35, wherein a method for detecting using the antibody which specifically recognizes a polypeptide consisting essentially of an amino acid sequence encoded by one of the sequences (a) to (e) or a part thereof is Western blotting, a dot blotting or a slot blotting.

40. The method according to claim 36, wherein a method for detecting using the antibody which specifically recognizes a polypeptide consisting essentially of an amino acid sequence encoded by one of the sequences (a) to (e) or a part thereof is Western blotting, a dot blotting or a slot blotting.

41. The method according to claim 37, wherein a method for detecting using the antibody which specifically recognizes a polypeptide consisting essentially of an amino acid sequence encoded by one of the sequences (a) to (e) or a part thereof is Western blotting, a dot blotting or a slot blotting.

42. The method according to claim 34, wherein a method for detecting using the antibody which specifically recognizes a polypeptide consisting essentially of an amino acid sequence encoded by one of the sequences (a) to (e) or a part thereof is a solid-phase enzyme immunoassay or a radioisotope immunoassay.

43. The method according to claim 35, wherein a method for detecting using the antibody which specifically recognizes a polypeptide consisting essentially of an amino acid sequence encoded by one of the sequences (a) to (e) or a part thereof is a solid-phase enzyme immunoassay or a radioisotope immunoassay.

44. The method according to claim 36, wherein a method for detecting using the antibody which specifically recognizes a polypeptide consisting essentially of an amino acid sequence encoded by one of the sequences (a) to (e) or a part thereof is a solid-phase enzyme immunoassay or a radioisotope immunoassay.

45. The method according to claim 37, wherein a method for detecting using the antibody which specifically recognizes a polypeptide consisting essentially of an amino acid sequence encoded by one of the sequences (a) to (e) or a part thereof is a solid-phase enzyme immunoassay or a radioisotope immunoassay.

47. The antibody according to claim 46, wherein the antibody specifically recognizes an amino acid sequence having the amino acid numbers 1-13 of SEQ ID No. 9 of the Sequence Listing or the amino acid numbers 1-14 of SEQ ID No. 10 of the Sequence Listing.

48. In a kit for testing a therapeutic or preventive agent for hyperlipidemia which includes an antibody, wherein the improvement comprises the antibody being the antibody of claim 46.

49. In a kit for testing a therapeutic or preventive agent for hyperlipidemia which includes an antibody, wherein the improvement comprises the antibody being the antibody of claim 47.

34. A method for testing the effect of a substance as a therapeutic or preventive agent for hyperlipidemia comprising:

(i) culturing cells in the presence or absence of a test substance;

(ii) detecting the amount of production of polypeptide having an amino acid sequence encoded by the nucleotide sequence of one of the following sequences (a) to (e) or a part thereof in a supernatant of the cultured cells obtained in step (i) using an antibody specifically recognizing the polypeptide;

(a) a nucleotide sequence having the nucleotide numbers 47-1411 of SEQ ID No. 1 of the Sequence Listing;

(b) a nucleotide sequence having the nucleotide numbers 78-1457 of SEQ ID No. 3 of the Sequence Listing;

(c) a nucleotide sequence of DNA incorporated into a phagemid carried by transformed Escherichia coli E.coli pBK/m55-1 SANK72199 (FERM BP-6940);

(d) a nucleotide sequence of DNA incorporated into a phagemid carried by transformed Escherichia coli E.coli pTrip/h55-1 SANK72299 (FERM BP-6941);

(e) a nucleotide sequence which hybridizes with a polynucleotide consisting essentially of an antisense sequence of a nucleotide sequence in one of the sequences (a) to (d) under stringent conditions, and encodes a polypeptide having an activity of raising neutral fat concentration in blood; and

(iii) comparing the amount of production of the polypeptide between the cells cultured in the absence of the substance and the cells cultured in the presence of the substance, as a result of that detected in step (ii).

46. An antibody which specifically recognizes a polypeptide consisting of the amino acid sequence encoded by one of the following sequences (a) to (e) or a part thereof:

(a) the nucleotide sequence having the nucleotide numbers 47-1411 of SEQ ID No. 1 of the Sequence Listing;

(b) the nucleotide sequence having the nucleotide numbers 78-1457 of SEQ ID No. 3 of the Sequence Listing;

(c) the nucleotide sequence of DNA incorporated into a phagemid carried by transformed Escherichia coli E.coli pBK/m55-1 SANK72199 (FERM BP-6940);

(d) the nucleotide sequence of DNA incorporated into a phagemid carried by transformed Escherichia coli E.coli pTrip/h55-1 SANK72299 (FERM BP-6941);

(e) the nucleotide sequence which hybridizes with a polynucleotide consisting essentially of an antisense sequence of a nucleotide sequence in one of the nucleotide sequences (a) to (d) under stringent conditions, and encodes a polypeptide having an activity of raising neutral fat concentration in blood.

50. A method for testing the effect of a substance as a therapeutic or preventive agent for hyperlipidemia comprising:

(i) administrating the substance to be tested to an animal other than a human obtained by genetic manipulation in which a foreign gene containing the nucleotide sequence of one of the following sequences (a) to (e) is introduced so that the expression of the gene can be detected;

(a) a nucleotide sequence having the nucleotide numbers 47-1411 of SEQ ID No. 1 of the Sequence Listing;

(b) a nucleotide sequence having the nucleotide numbers 78-1457 of SEQ ID No. 3 of the Sequence Listing;

(c) a nucleotide sequence of DNA incorporated into a phagemid carried by transformed Escherichia coli E.coli pBK/m55-1 SANK72199 (FERM BP-6940);

(d) a nucleotide sequence of DNA incorporated into a phagemid carried by transformed Escherichia coli E.coli pTrip/h55-1 SANK72299 (FERM BP-6941);

(e) a nucleotide sequence which hybridizes with a polynucleotide consisting essentially of an antisense sequence of the nucleotide sequence of one of the nucleotide sequences (a) to (d) under stringent conditions, and encodes a polypeptide having an activity of raising neutral fat concentration in blood; and

(ii) measuring the concentration of neutral-fat in the blood of the animal in step (i).

51. The method according to claim 50 wherein the animal other than a human in step (i) is a mouse.

52. The method according to claim 50 wherein the method for introducing the foreign gene to the non-human animal comprises infecting the animal with an adenovirus which contains an adenovirus vector in which the gene was introduced.

53. An antibody for testing a therapeutic or preventive agent for hyperlipidemia which specifically recognizes a polypeptide consisting essentially of the amino acid sequence having the amino acid numbers 17-455 of SEQ ID No. 2 of the Sequence Listing or a part thereof, a polypeptide which consists essentially of the amino acid sequence having the amino acid numbers 19-455 of SEQ ID No. 2 of the Sequence Listing or a part thereof, or a polypeptide which consists essentially of the amino acid sequence having the amino acid numbers 17-460 of SEQ ID No. 4 of the Sequence Listing or a part thereof.

54. In a test kit for a therapeutic or preventive agent for hyperlipidemia which includes an antibody, wherein the improvement comprises the antibody being an antibody that specifically recognizes a polypeptide consisting essentially of the amino acid sequence having the amino acid numbers 17-455 of SEQ ID No. 2 of the Sequence Listing or a part thereof, a polypeptide which consists essentially of the amino acid sequence having the amino acid numbers 19-455 of SEQ ID No. 2 of the Sequence Listing or a part thereof, or a polypeptide which consists essentially of the amino acid sequence having the amino acid numbers 17-460 of SEQ ID No. 4 of the Sequence Listing or a part thereof.

55. A DNA or RNA consisting essentially of an antisense sequence of the nucleotide sequence which consists essentially of a continuous 15 or 30 nucleotides in the nucleotide sequence having the nucleotide numbers 78-1457 of SEQ ID No. 3 of the Sequence Listing.

56. A therapeutic composition for treating hyperlipidemia containing a pharmaceutically effective amount of the DNA or RNA of claim 55 in combination with a pharmaceutically acceptable carrier.